ArticleFrontiers in immunology2026
Shaping the founders: naïve CD4 T cell heterogeneity in people with HIV-1 or HIV-2.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naïve CD4 T cells harbour functional subsets that influence the quality of immune reconstitution and the persistent viral reservoirs in people with HIV (PWH) under antiretroviral therapy (ART). Here, we profiled the circulating naïve CD4 T cells from PWH under effective ART with distinct past histories of viral burden, namely starting treatment early in acute or late in chronic stage HIV-1 infection, and people with HIV-2 (PWH2), who feature low to undetectable viremia before ART and slow disease progression. Spectral flow cytometry enabled us to capture the heterogeneity of this overlooked T cell compartment. Early-treated PWH1 maintained a naïve CD4 T cell profile comparable to that of age-matched seronegative individuals. Late-treated PWH1 and PWH2 showed distinct imbalances in conventional and regulatory subpopulations, yet both exhibited a relative expansion of CD31-expressing naïve cells, consistent with an IL-7-mediated homeostatic response. The ability of purified naïve CD4 T cells to respond to IL-7 was evaluated in additional cohorts of untreated PWH, revealing reduced proliferation and increased p21 transcription in PWH1 elite controllers. Additionally, a significant decline in proviral DNA was found in PWH2, suggesting an impact of IL-7 on HIV-2-infected naïve CD4 T cells that was not observed in the case of HIV-1 infection. Unravelling the homeostatic pathways and functional implications of naïve CD4 T cell heterogeneity will help clarify viral reservoir dynamics and inflammation in PWH and define strategies to prevent immune senescence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.